Skip to main content
. Author manuscript; available in PMC: 2009 Oct 25.
Published in final edited form as: Exp Neurol. 2005 Dec 9;197(2):363–372. doi: 10.1016/j.expneurol.2005.10.022

Fig. 5.

Fig. 5

Response of AAV-AADC-treated monkeys to acute l-dopa. (A) Clinical responses to acute administration of l-dopa (0, 5, 10, 20 mg/kg) were rated at 45 min. A 3-day wash-out was implemented between each dose. Improved l-dopa response was seen by reduction of CRS scores after AADC gene transfer. However, it was associated with significantly elevated dyskinesias as shown in panel B. (B) The animals received weekly injections of increasing doses of l-dopa: 1.5, 2.5, 5, 10, 20, 30 mg/ml combined with the decarboxylase inhibitor benserazide (2 mg/kg) and dyskinesias were scored. The dyskinesia scores of animals treated with AAV-AADC were averaged for each l-dopa dose before and after surgery and are reported as mean ± SEM.